US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrollment of first patient in phase 3 trial.
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Monday.
Shares of Biohaven Ltd (NASDAQ:BHVN) fell sharply in pre-market trading.
Biohaven announced enrollment of first patient in its pivotal Phase 3 trial of BHV-1300 for Graves' disease.
B of A Securities analyst Jason Gerberry downgraded Biohaven from Neutral to Underperform and lowered the price target from $12 to $11.
Biohaven shares tumbled 5.2% to $15.00 in pre-market trading.
Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahead of key epilepsy trial data.
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Monday.
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biohaven Ltd. (BHVN) and Abivax SA…
RBC's $22 price target implies an upside of 74% for shares of Biohaven.
US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.35 each, shares down 9% in…
U.S. stock futures rise, Nasdaq up 1%. Graham Corp shares down 8.7%. Other stocks declining in pre-market trading: BVC, TLK,…
